Acumed LLC04.04.19
Acumed, a manufacturer of orthopaedic surgical solutions,has acquired technology that will help the company provide a total elbow arthroplasty (TEA) solution to the market.
Purchased from Bluefish Orthopedics LLC for an undisclosed amount, the technology was designed by orthopedic surgeons Andrew Palmer, M.D., of Eastham, Mass., and Dale Dellacqua, M.D., of Bloomington, Ill.
The total elbow product will complement Acumed’s elbow portfolio, which includes Anatomic Radial Head solutions, the Radial Head Plating System, the Elbow Plating System, and the Acutrak 2 Headless Compression Screw. “This acquisition will accelerate Acumed’s opportunity to build on the technology and deliver a compelling solution to address the unmet need for optimal total elbow replacement,” said Acumed President and CEO Sharon Wolfington.
The elbow replacement market was estimated at approximately $47 million globally in 2017 and is expected to reach $59 million by 2023. Jagi Gill, vice president and general manager of AcuVentures, stated, “We are excited to develop this disruptive technology from Bluefish Orthopedics with the goal of leveraging the best practices within our organization to deliver a clinically impactful treatment solution to the surgeon community.”
Headquartered in Hillsboro, Ore., with a global distribution network and offices worldwide, Acumed is a company dedicated to innovative and quality medical device solutions. The firm produces over 90 percent of its implants in the United States.
Purchased from Bluefish Orthopedics LLC for an undisclosed amount, the technology was designed by orthopedic surgeons Andrew Palmer, M.D., of Eastham, Mass., and Dale Dellacqua, M.D., of Bloomington, Ill.
The total elbow product will complement Acumed’s elbow portfolio, which includes Anatomic Radial Head solutions, the Radial Head Plating System, the Elbow Plating System, and the Acutrak 2 Headless Compression Screw. “This acquisition will accelerate Acumed’s opportunity to build on the technology and deliver a compelling solution to address the unmet need for optimal total elbow replacement,” said Acumed President and CEO Sharon Wolfington.
The elbow replacement market was estimated at approximately $47 million globally in 2017 and is expected to reach $59 million by 2023. Jagi Gill, vice president and general manager of AcuVentures, stated, “We are excited to develop this disruptive technology from Bluefish Orthopedics with the goal of leveraging the best practices within our organization to deliver a clinically impactful treatment solution to the surgeon community.”
Headquartered in Hillsboro, Ore., with a global distribution network and offices worldwide, Acumed is a company dedicated to innovative and quality medical device solutions. The firm produces over 90 percent of its implants in the United States.